From startups to legacy brands, you're making your mark. We're here to help.
Key Links
Prepare for future growth with customized loan services, succession planning and capital for business equipment.
Key Links
Institutional Investing
Serving the world's largest corporate clients and institutional investors, we support the entire investment cycle with market-leading research, analytics, execution and investor services.
Key Links
Providing investment banking solutions, including mergers and acquisitions, capital raising and risk management, for a broad range of corporations, institutions and governments.
Key Links
A uniquely elevated private banking experience shaped around you.
Whether you want to invest on your own or work with an advisor to design a personalized investment strategy, we have opportunities for every investor.
Explore a variety of insights.
Key Links
Insights by Topic
Explore a variety of insights organized by different topics.
Key Links
Insights by Type
Explore a variety of insights organized by different types of content and media.
Key Links
We aim to be the most respected financial services firm in the world, serving corporations and individuals in more than 100 countries.
Key Links
Biopharma companies are showing signs of recovery as they work through another quarter of deal and funding challenges. On the medtech front, activity remains muted—but there are pockets of positive data.
Biopharma venture activity increased in the second quarter of 2023, even as R&D partnerships declined to their lowest quarterly volume in more than five years.
J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight on industry trends that will shape the back half of 2023. The reports, powered by DealForma, highlight:
Download the full reports to better understand these dealmaking trends.
Outlook
Weighing the impact of a potential Trump victory
Aug 21, 2024
Four priorities for the Republican ticket – trade policy, taxes, immigration and industrial spending – will have an impact on markets and the economy. What might it be?
Outlook
July 2024 CPI report: Inflation continues to cool, paving the way for rate cuts
Aug 15, 2024
The July 2024 CPI report will likely increase the Fed’s confidence that inflation is on the way to its 2% target and position the Fed to cut interest rates in September. Learn more here.
Outlook
A new presidential race is on – know the potential investment implications
Aug 08, 2024
J.P. Morgan Wealth Management recently presented a webcast about the 2024 election and its market implications. Here are the key points investors should pay attention to.
Outlook
Eye on the Market: There’s no place like home
Aug 06, 2024
In the latest Eye on the Market: There’s No Place Like Home, Michael Cembalest, Chairman of Market and Investment Strategy for J.P. Morgan Asset and Wealth Management, unpacks recent market movement and work-from-home trends.
Outlook
July 2024 Jobs Report: 114,000 jobs added, a sharp slowdown from June
Aug 05, 2024
The U.S. economy added significantly less jobs than expected in July, making a September interest rate cut from the Federal Reserve even more likely.
Outlook
Innovation economy midyear outlook
Aug 02, 2024
Our report explores major trends impacting the innovation economy, including venture fundraising, investment, valuations and the exit environment.
Outlook
July 2024 Fed meeting: Rates remain steady for another month
Aug 01, 2024
The Federal Reserve held rates steady in July, but left the door open to a possible rate cut in September.
Outlook
Biopharma and medtech venture investments rise in Q2
Jul 29, 2024
Our Biopharma and Medtech Licensing and Venture Reports explore upfront cash, mergers, acquisitions and other trends seen in the second quarter of 2024.
You're now leaving J.P. Morgan
J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.